在更新的前列腺癌症NCCN指南中，Veracyte的解密前列腺测试在分子测试中获得最高证据水平评级-动脉网

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

BioSpace 等信源发布 2024-02-27 15:05



可切换为仅中文







SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.

加利福尼亚州南旧金山——（商业新闻短讯）——领先的癌症诊断公司Veracyte，Inc.（纳斯达克：VCYT）今天宣布，其Decipher前列腺基因组分类器是2024年NCCN*肿瘤学临床实践指南（NCCN Guidelines®）中唯一获得“1B级”证据评级的基因表达测试作为局部前列腺癌患者危险分层的预后工具。

Level 1B was assigned to Decipher Prostate based on the evidence in both the post-biopsy and post-prostatectomy settings. Additionally, because of this classification, the Decipher Prostate test is the only gene expression test for which the guidelines synthesize the available published data in a separate table that summarizes treatment implications for patients based on both their NCCN risk classification and Decipher score..

根据活检后和前列腺切除术后的证据，将1B级分配给解密前列腺。此外，由于这种分类，Decipher前列腺测试是唯一的基因表达测试，指南在单独的表格中综合了可用的已发布数据，该表格根据患者的NCCN风险分类和Decipher评分总结了对患者的治疗意义。。

“We commend the NCCN panel for their evidence synthesis and expert consensus that has again designated the Decipher Prostate test as the gene expression tool for risk stratification supported by the most clinical evidence across the spectrum of the disease and has uniquely provided clinical guidance that integrates a patient’s Decipher score,” said Elai Davicioni, Ph.D., medical director of Urology for Veracyte.

Elai Davidioni博士说：“我们赞扬NCCN小组的证据综合和专家共识，他们再次将Decipher前列腺测试指定为风险分层的基因表达工具，该工具得到了该疾病范围内大多数临床证据的支持，并独特地提供了整合患者Decipher评分的临床指导。”。，Veracyte泌尿科医学主任。

“These recommendations reflect the extensive clinical evidence generated in collaboration with clinical trial groups from around the world from analysis of many thousands of their patients, including those from practice-changing phase 3 studies. Ultimately, we believe that these guidelines will help our customers better use the Decipher Prostate test and tumor biology to provide optimal care for more of their patients with prostate cancer.”.

“这些建议反映了与来自世界各地的临床试验小组合作，通过对数千名患者的分析，包括那些来自改变实践的3期研究的患者，产生了广泛的临床证据。最终，我们相信这些指南将帮助我们的客户更好地使用Decipher前列腺测试和肿瘤生物学，为患者提供最佳护理更多的前列腺癌患者。”。

The new NCCN Guidelines classify the Decipher Prostate test as Level 1B according to the “Simon Criteria,” which are published criteria for assigning a level of evidence for clinical biomarkers based on the quality and quantity of evidence available. They summarize the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials..

新的NCCN指南根据“西蒙标准”将Decipher前列腺测试分类为1B级，该标准是根据可用证据的质量和数量为临床生物标志物分配证据水平的公开标准。他们根据Decipher评分和多个随机3期临床试验分析的已发表证据总结了对患者的治疗意义。。

About the Decipher Prostate Genomic Classifier

关于Decipher前列腺基因组分类器

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment.

解密前列腺基因组分类器是一种22基因测试，使用RNA全转录组分析和机器学习开发，有助于为前列腺癌患者的治疗决策提供信息。该测试是在活检或手术切除的样本上进行的，并通过标准治疗提供了发生转移的准确风险。

Armed with this information, the physician can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in more than 75 studies involving more than 100,000 patients..

有了这些信息，医生可以更好地个性化患者的护理，并可能为风险较低的患者推荐不那么密集的选择，或者为转移风险较高的患者推荐更早，更密集的治疗。Decipher前列腺测试已经在超过75项涉及100000多名患者的研究中得到验证。。

About Veracyte

关于Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development.

Veracyte（纳斯达克股票代码：VCYT）是一家全球诊断公司，其愿景是为全世界的患者转变癌症护理。我们为临床医生提供所需的高价值见解，以指导和确保患者在诊断和治疗癌症的关键时刻。我们的Veracyte Diagnostics平台提供了高性能的癌症测试，这些测试由广泛的基因组和临床数据，深入的生物信息学和人工智能能力以及强大的证据生成引擎提供支持，最终推动了我们测试的持久报销和指南纳入，以及支持持续创新和管道开发的新见解。

For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte..

欲了解更多信息，请访问www.veracyte.com，并在X（原推特）上关注该公司@veracyte。。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release contains forward-looking statements, including, but not limited to our statements related to the potential NCCN Guidelines impact on physician’s better use of the Decipher prostate test. to our expectations the Decipher prostate test helps physicians better personalize their patients’ care in recommending less intensive versus more intensive treatment options.

本新闻稿包含前瞻性声明，包括但不限于我们有关NCCN指南对医生更好地使用Decipher前列腺测试的潜在影响的声明。根据我们的预期，Decipher前列腺测试有助于医生更好地个性化患者的护理，推荐强度较低的治疗方案和强度较高的治疗方案。

Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements.

前瞻性陈述可以用“出现”、“预期”、“打算”、“计划”、“预期”、“相信”、“应该”、“可能”、“将”、“启用”、“定位”、“提议”、“设计”等词语来识别，以及类似的未来时期的引用。实际结果可能与任何前瞻性声明中预测或建议的结果存在重大差异。

These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the impact we believe these guidelines will have in helping our customers better use the Decipher Prostate test and tumor biology to provide optimal care for more of their patients with prostate cancer.

这些陈述涉及风险和不确定性，这可能导致实际结果与我们的预测存在实质性差异，并且包括但不限于我们认为这些指南将对帮助我们的客户更好地使用Decipher前列腺测试和肿瘤生物学提供的影响，为更多的前列腺癌患者提供最佳护理。

Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023 and our Quarterly Report on Form 10-Q filed for the three months ended September 30, 2023, filed on November 8, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com.

可能影响这些前瞻性陈述的其他因素可以在2023年3月1日提交的10-K表年度报告和2023年11月8日提交的截至2023年9月30日的三个月10-Q表季度报告中的“风险因素”标题下找到。这些文件的副本（如有）可在我们网站的投资者部分找到，网址为https://investor.veracyte.com.

These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwi.

这些前瞻性声明仅在本协议签署之日有效，除法律要求外，我们明确否认有义务更新这些前瞻性声明或实际结果可能不同的原因，无论是由于新信息、未来事件或其他原因。

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Veracyte、Veracyte徽标和Decipher是Veracyte，Inc.及其子公司在美国和选定国家的注册商标。

* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*国家综合癌症网络。NCCN对其内容、使用或应用不作任何形式的保证，并对其应用或以任何方式使用不承担任何责任。

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227639570/en/

在businesswire.com上查看源版本：https://www.businesswire.com/news/home/20240227639570/en/

Contacts

联系人

Investors:

投资者：

Shayla Gorman

investors@veracyte.com

619-393-1545

Media:

媒体：